Citations

Showing 10 of 108162 citations.

Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Bone Marrow
Peterson, Lo Ann C., Agosti, Steven J., Hoyer, James D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 9 | Pages: 1050-1056

10.5858/2002-126-1050-pfteos | PMID 12240626 Get It

Prognostic Value of the Erythrocyte Sedimentation Rate in Patients With Unstable Angina
Wu, Lambert A., Tan, Shen-Li, Wright, R. Scott, Kopecky, Stephen L. , Burritt, Mary F., Santrach, Paula J., Frye, Robert L. , Liu, Julia J.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 7 | Pages: 772

10.5858/2002-126-0772-pvotes | PMID 12125644 Get It

Outpatient Phlebotomy Success and Reasons for Specimen Rejection
Dale, Jane C., Novis, David A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 4 | Pages: 416-419

10.5858/2002-126-0416-opsarf | PMID 11900564 Get It

Abstract Objectives.—To determine the rate with which blood collection is successful on the initial phlebotomy encounter, the rate with which laboratory personnel judge specimens unsuitable for analysis, and the practice characteristics associated with fewer unsuccessful collections and fewer rejected specimens. Design.—Clinical laboratories participating in the College of American Pathologists Q-Probes laboratory improvement program prospectively characterized the outcome of outpatient phlebotomies for 3 months or until 20 unsuccessful phlebotomy encounters occurred. By questionnaire, participants provided information about test ordering, patient preparation, and specimen collection. Setting and Participants.—Institutions in the United States (n = 202), Canada (n = 4), Australia (n = 3), and South Korea (n = 1). Main Outcome Measures.—Percentage of successful encounters and percentage of unsuitable specimens. Results.—Of 833289 encounters, 829723 were successful. Phlebotomies were unsuccessful because patients were not fasting as directed (32.2%), phlebotomy orders were missing information (22.5%), patients specimens were difficult to draw (13.0%), patients left the collection area before specimens were collected (11.8%), patients were improperly prepared for reasons other than fasting (6.3%), patients presented at the wrong time (3.1%), or for other reasons (11.8%). Only 2153 specimens (0.3%) were unsuitable; these samples were hemolyzed (18.1%), of insufficient quantity (16.0%), clotted (13.4%), lost or not received in the laboratory (11.5%), inadequately labeled (5.8%), at variance with previous or expected results (4.8%), or unacceptable for other reasons (31.1%). Facilities staffed by laboratory-administered phlebotomists reported higher success rates than facilities staffed by nonlaboratory-administered phlebotomists (P = .002). Conclusions.—Most outpatient phlebotomy encounters are successful and result in specimens suitable for laboratory analysis.
Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry
Domecq, Juan Pablo , Lal, Amos , Sheldrick, Christopher R., Kumar, Vishakha K. , Boman, Karen , Bolesta, Scott , Bansal, Vikas , Garcia, Michael A. , Kaufman, Margit, Danesh, Valerie , Anderson, Harry L., Milligan, Patrick S., Denson, Joshua L. , Hill, Catherine A. St., Dodd, Kenneth W. , Gajić, Ognjen, Kashyap, Rahul , Tierney, David M. , Camazine, Maraya , Dapul, Heda , Gharpure, Varsha , Koritala, Thoyaja , Заболотских, И. Б. , Kovačević, Peđja , Asghar, Muhammad Sohaib , McGonagill, Patrick W. , El‐Kassas, Mohamed , Parameswaran, Sreejith , Iwasaki, Yudai , Nenadić, Irina , Djuric, Marko , Lutrick, Karen , Lumelsky, David , Minear, Steven , Tarabichi, Yasir , Dy, Rajany , Galet, Colette , West, T. Eoin , Wilfong, Erin M. , Ramírez, Michelle , Law, Anica C. , Lal, Amos , Bansal, Vikas , Denson, Joshua L , Kashyap, Rahul , Gharpure, Varsha P , Asghar, Muhammad S , Domecq Graces, Juan Pablo , Sheldrick, Christopher R., Harhay, Michael Oscar , Cheruku, Sreekanth , Banner‐Goodspeed, Valerie , Anderson, Harry L., Martin, Greg S. , Gajic, Ognjen , Walkey, Allan J.

Mayo Clinic

Critical Care Medicine | January 29, 2021 | Volume: 49 | Issue: 3 | Pages: 437-448

10.1097/ccm.0000000000004879 | PMID 33555777 Get It

OBJECTIVES: To describe the outcomes of hospitalized patients in a multicenter, international coronavirus disease 2019 registry. DESIGN: Cross-sectional observational study including coronavirus disease 2019 patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection between February 15, 2020, and November 30, 2020, according to age and type of organ support therapies. SETTING: About 168 hospitals in 16 countries within the Society of Critical Care Medicine’s Discovery Viral Infection and Respiratory Illness University Study coronavirus disease 2019 registry. PATIENTS: Adult hospitalized coronavirus disease 2019 patients who did and did not require various types and combinations of organ support (mechanical ventilation, renal replacement therapy, vasopressors, and extracorporeal membrane oxygenation). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Primary outcome was hospital mortality. Secondary outcomes were discharge home with or without assistance and hospital length of stay. Risk-adjusted variation in hospital mortality for patients receiving invasive mechanical ventilation was assessed by using multilevel models with hospitals as a random effect, adjusted for age, race/ethnicity, sex, and comorbidities. Among 20,608 patients with coronavirus disease 2019, the mean (± sd ) age was 60.5 (±17), 11,1887 (54.3%) were men, 8,745 (42.4%) were admitted to the ICU, and 3,906 (19%) died in the hospital. Hospital mortality was 8.2% for patients receiving no organ support ( n = 15,001). The most common organ support therapy was invasive mechanical ventilation ( n = 5,005; 24.3%), with a hospital mortality of 49.8%. Mortality ranged from 40.8% among patients receiving only invasive mechanical ventilation ( n =1,749) to 71.6% for patients receiving invasive mechanical ventilation, vasoactive drugs, and new renal replacement therapy ( n = 655). Mortality was 39% for patients receiving extracorporeal membrane oxygenation ( n = 389). Rates of discharge home ranged from 73.5% for patients who did not require organ support therapies to 29.8% for patients who only received invasive mechanical ventilation, and 8.8% for invasive mechanical ventilation, vasoactive drugs, and renal replacement; 10.8% of patients older than 74 years who received invasive mechanical ventilation were discharged home. Median hospital length of stay for patients on mechanical ventilation was 17.1 days (9.7-28 d). Adjusted interhospital variation in mortality among patients receiving invasive mechanical ventilation was large (median odds ratio 1.69). CONCLUSIONS: Coronavirus disease 2019 prognosis varies by age and level of organ support. Interhospital variation in mortality of mechanically ventilated patients was not explained by patient characteristics and requires further evaluation.
Clinical Trials in Vascular Gene Therapy
Simari, Robert D., O’Brien, Timothy

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 3 | Pages: 317-319

10.5858/2002-126-0317-ctivgt | PMID 11860306 Get It

Abstract Objective. —Vascular gene transfer provides unique opportunities for novel therapies for cardiovascular disease. To define the limitations and expectations of translating preclinical strategies to clinical therapy, the kinetics and extent of vascular transgene expression must be determined. Data Sources. —Published clinical and preclinical studies of vascular gene transfer. Data Extraction. —Kinetics and extent of vascular transgene expression. Data Synthesis. —In spite of ongoing clinical studies in vascular gene transfer, data regarding the kinetics and extent of transgene expression are very limited. Conclusions. —For the efficient translation of preclinical to clinical vascular gene transfer studies, the kinetics and extent of transgene expression should be determined. Novel imaging technologies and unique clinical scenarios for obtaining tissue should be considered.
Testicular Natural Killer/T-Cell Lymphoma, Nasal Type, of True Natural Killer–Cell Origin
Totonchi, Kameel F., Engel, George, Weisenberg, Elliot, Rhone, Douglas P., Macon, William R.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 12 | Pages: 1527-1529

10.5858/2002-126-1527-tnktcl | PMID 12456216 Get It

Abstract The majority of primary testicular lymphomas are of B-cell type. Other primary lymphomas are rarely encountered in the testes. Natural killer (NK)/T-cell lymphomas of nasal type are aggressive extranodal lymphomas associated with Epstein-Barr virus infection that are usually encountered in the upper aerodigestive tract. They also occur in the skin, soft tissue, and colon. Primary testicular NK/T-cell lymphomas are rarely reported. We describe the case of a 66-year-old Korean man who presented with right-sided painless testicular enlargement and underwent radical orchiectomy. Histologic examination revealed an angiocentric and angioinvasive infiltrate of medium to large tumor cells with moderately abundant pale pink cytoplasm and folded and indented pleomorphic nuclei. Paraffin immunohistochemical studies showed positivity of the tumor cells for CD45, TIA-1, granzyme B, CD56, and CD3ɛ. In situ hybridization showed diffuse positivity for Epstein-Barr virus–encoding RNA. The results of gene rearrangement studies for the γ chain of the T-cell receptor were negative. The results of paraffin immunohistochemical studies for CD20, CD8, CD45RO, beta f1, and ALK-1 were negative. An extensive workup showed no evidence of lymphoma outside the testes. We report a rare case of primary testicular NK/T-cell lymphoma of the nasal type of true NK-cell origin.
Testing for Group A Streptococci
Dale, Jane C., Novak, Robert W., Higgens, Patricia, Wahl, Elmer F.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 12 | Pages: 1467-1470

10.5858/2002-126-1467-tfgas | PMID 12456206 Get It

Abstract Context.—Laboratory diagnosis of group A streptococcal pharyngitis in physician office and small-hospital laboratories. Objective.—To characterize laboratory practices for the diagnosis of group A streptococcal pharyngitis and to identify opportunities for improvement. Design.—Voluntary self-assessment questionnaire, used to assess the laboratory practices of 790 laboratories subscribing to the College of American Pathologists Excel Microbiology Proficiency Testing Program. Results.—We observed discrepancies between self-reported and recommended specimen collection and laboratory testing practices for some laboratories. The most notable discrepancies were failing to provide a written specimen-collection procedure (17.8%), sampling the tongue and oral mucosa (2%), failing to always perform back-up cultures when rapid antigen test results were negative (57.5%), and finalizing culture reports within 24 hours or less (34.0%). Additionally, among those respondents who used the bacitracin disk, 57.9% (277 respondents) applied the disk directly onto a primary plate. Conclusions.—Opportunities exist to improve testing practices for the diagnosis of group A streptococcal pharyngitis for some physician office and small-hospital laboratories.
Proficiency Testing for Laboratories Performing Fluorescence In Situ Hybridization With Chromosome-Specific DNA Probes
Mascarello, James T., Brothman, Arthur R., Davison, Keri, Dewald, Gordon W., Herrman, Marille, McCandless, Danette, Park, Jonathan P., Persons, Diane L., Rao, Kathleen W., Schneider, Nancy R., Vance, Gail H. , Cooley, Linda D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 12 | Pages: 1458-1462

10.5858/2002-126-1458-ptflpf | PMID 12456204 Get It

Abstract Objective.—To assess laboratory performance, use, and limitations in the joint College of American Pathologists and American College of Medical Genetics proficiency testing program for laboratories performing cytogenetic tests based on fluorescence in situ hybridization (FISH). Data Sources.—Eight proficiency surveys dealing with FISH detection of microdeletions or microduplications, aneuploidy in interphase cells, gene amplification, and neoplasm-specific translocations. Participating laboratories used their own DNA probes (commercial or home-brew), hybridization methods, and analytic criteria to answer clinical questions about cases represented by slides included in the survey materials. They also described their test results according to the International System for Human Cytogenetic Nomenclature (ISCN) and answered supplementary questions relating to their experience with the subject test systems. Data Extraction.—In addition to evaluating diagnostic accuracy, we evaluated survey use, laboratory experience, variation in methodologic approach, and the practicality of using ISCN nomenclature for describing test results. Synthesis and Conclusions.—With the exception of one challenge, at least 80% of the participants reached the correct diagnostic conclusion. In the sole exception, there was still a consensus of 91.7% of participants with the same (albeit erroneous) diagnostic conclusion. The overall outstanding performance of participating laboratories clearly shows the reliability of current FISH methods. Despite the fact that a large number of laboratories reported little or no experience with the specific test systems, the overwhelming majority performed very well. This result shows that the program's strategy of targeting classes of abnormalities (vs a single abnormality associated with a specific disease) did not put at a disadvantage participants who did not routinely perform all of the potential tests in the class. The extraordinary variation in ISCN descriptions submitted by participants showed that the existing system for human cytogenetic nomenclature is not suitable for facile communication of FISH test results.
Bronchial Carcinoid Tumor With Crystalloid Cytoplasmic Inclusions
Grogg, Karen L., Padmalatha, C., Leslie, Kevin O., Padmalatha, Chandrashekar

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 126 | Issue: 1 | Pages: 93-96

10.5858/2002-126-0093-bctwcc | PMID 11800658 Get It

Abstract We report a bronchial carcinoid tumor with distinctive, cytoplasmic, rod-shaped crystalloid inclusions that were visible by light microscopy. These cytoplasmic structures were immunoreactive with antibodies against chromogranin A and synaptophysin in paraffin-embedded tissue. Ultrastructural studies showed them to be paracrystalline in nature and located within lysosomes. This case highlights an interesting, and potentially confusing, histologic manifestation in an otherwise typical bronchial carcinoid tumor.
Defining DISI and VISI
Braun, Natalie , Berger, Richard A. , Wolfe, Scott W.

Mayo Clinic

Journal of Hand Surgery (European Volume) | January 29, 2021 | Volume: 46 | Issue: 5 | Pages: 566-568

10.1177/1753193421989933 | PMID 33509029 Get It